Physician profile
William Stephen Denson
NPI 1760495907
$1,362.48
in general payments reported to CMS, 2019-2025
14 companies · $15.92 in 2025
The $15.92 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $79.74 · 2021: $506 · 2022: $226 · 2023: $133 · 2024: $19.83 · 2025: $15.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $409.30 | 2019-2022 | |
| Abbvie INC. | $354.81 | 2021-2023 | Qulipta |
| Teva Pharmaceuticals USA, INC. | $237.67 | 2019-2021 | |
| Ucb, INC. | $172.80 | 2019-2025 | Briviact |
| Neurelis, INC. | $35.95 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $19.95 | 2023 | |
| Pfizer INC. | $19.83 | 2024 | |
| Lilly USA, LLC | $19.50 | 2019 | |
| Genzyme Corporation | $17.22 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.50 | 2020 | |
| Acadia Pharmaceuticals INC | $16.31 | 2021 | |
| Ge Healthcare | $15.36 | 2022 | |
| Tanabe Pharma America, INC. | $14.80 | 2021 | |
| Allergan, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Denson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.